Sex related differences in acute and recurrent pericarditis: A narrative review Authors: Nouf Alanazi Published: 2026 ABSTRACT BackgroundAcute and recurrent pericarditis represent significant clinical challenges, with growing evidence suggesting important sex-related differences in their presentation, etiology, and course. This review synthesizes current knowledge on these disparities.MethodsGiven the heterogeneity of available evidence and the limited number of studies with sex-specific analyses, this review was conducted in a narrative format.DiscussionWhile acute pericarditis is more prevalent in men, particularly at a younger age and often due to idiopathic or viral causes, women are more frequently affected at an older age and similarly mostly due to viral or idiopathic causes; however, women exhibit a stronger association with autoimmune etiologies compared to men. The clinical presentation also diverges, with men more often presenting with classic features like chest pain, pericardial rub, and characteristic electrocardiographic changes, whereas women may present with atypical features. A critical finding is that women face a higher burden of recurrent pericarditis, experiencing more frequent and severe episodes, which may be linked to their higher prevalence of autoimmune conditions and the subsequent greater use of corticosteroid therapy, which is a known risk factor for recurrence.ConclusionDistinct sex-related patterns in acute and recurrent pericarditis necessitate a more tailored diagnostic and therapeutic approach. Further large-scale studies are warranted to definitively establish the links between sex hormones, autoimmune predisposition, and treatment outcomes to optimize patient care for both men and women. Introduction Sex-related differences in cardiac disease are well established, with distinct pathophysiology and outcomes [1]. Sex is an increasingly recognised determinant in pericardial diseases, including acute and recurrent pericarditis. These differences influence presentation, progression, treatment response, and prognosis [2]. Acute pericarditis is more common in men, particularly the young, with higher incidence rates. Recent cohort data show a significantly higher adjusted risk in men [3]. In contrast, women often have a distinct clinical and etiological profile, including delayed onset and atypical findings, contributing to diagnostic challenges [4]. Recurrent pericarditis affects 15–30% of patients after the initial episode, with around 50% experiencing multiple recurrences. Women, particularly those with autoimmune disorders, appear more susceptible, which suggests possible underlying sex-specific immune mechanisms. Advancements in imaging and targeted therapies have improved disease management. However, few clinical trials include sex-specific analyses [5], and modern sex-stratified cohorts do not show consistent differences in prognostic features such as pericardial effusion burden, hospitalisation rates, or short-term outcomes after diagnosis. This indicates that, when managed according to guideline-directed therapy, the disease course is broadly similar between women and men [6]. This underscores the need for sex-informed approaches in the diagnosis and management of pericardial disease. Consideration of biological, immunological, and sociocultural factors is essential to improve diagnostic accuracy, tailor therapy, and reduce disparities in outcomes for acute and recurrent pericarditis. This review summarizes the principal sex-related differences in epidemiology, etiology, clinical presentations, management, and outcomes of acute and recurrent pericarditis, and addresses key considerations during pregnancy. Table 1 shows the key sex-related differences in acute and recurrent pericarditis.Table 1Sex-related differences in acute and recurrent pericarditis.MalesFemalesEpidemiologyHigher incidence of acute idiopathic/viral pericarditis; male predominance in first episodesHigher incidence of recurrent pericarditis, especially with autoimmune backgroundAge at presentationTypically, younger at first episodeOften older at first presentation; more comorbiditiesEtiologyMore likely idiopathic or viralSimilarTriggersViral infections more commonAutoimmune flares, hormonal transitions (pregnancy/postpartum), and systemic inflammation more commonClinical presentationMore “classic” symptoms: sharp pleuritic pain, friction rub, typical ECG changesMore atypical symptoms; less frequent classic ECG changes; more subacute or smoldering presentationsDiagnostic delaysLess commonMore common due to atypical symptoms, gender bias, and lower suspicion of pericardial diseaseECG findingsTypical diffuse ST-elevation more frequentLess typical ECG patterns; lower sensitivity of classic criteriaTreatment patternsRespond well to NSAIDs + colchicineMore frequent corticosteroid use; higher need for immunomodulators (azathioprine, IVIG, IL-1 inhibitors)Recurrence riskLower overall recurrence ratesHigher recurrence rates, especially with autoimmune disease or steroid exposureAutoimmune comorbidityLess commonMuch more common; major driver of recurrencePain perception & reportingMore likely to report classic chest painMore likely to report atypical pain, fatigue, systemic symptomsHealth-seeking behaviorEarlier presentationLater presentationClinician biasPericarditis more readily suspectedSymptoms more often attributed to non-cardiac causesPregnancy considerationsNot applicablePregnancy/postpartum may trigger flares; colchicine now considered safe; IL-1 inhibitors used selectivelyOutcomesGenerally favorable with standard therapyHigher burden of symptoms, more relapses, greater need for advanced therapies Table 1Sex-related differences in acute and recurrent pericarditis.MalesFemalesEpidemiologyHigher incidence of acute idiopathic/viral pericarditis; male predominance in first episodesHigher incidence of recurrent pericarditis, especially with autoimmune backgroundAge at presentationTypically, younger at first episodeOften older at first presentation; more comorbiditiesEtiologyMore likely idiopathic or viralSimilarTriggersViral infections more commonAutoimmune flares, hormonal transitions (pregnancy/postpartum), and systemic inflammation more commonClinical presentationMore “classic” symptoms: sharp pleuritic pain, friction rub, typical ECG changesMore atypical symptoms; less frequent classic ECG changes; more subacute or smoldering presentationsDiagnostic delaysLess commonMore common due to atypical symptoms, gender bias, and lower suspicion of pericardial diseaseECG findingsTypical diffuse ST-elevation more frequentLess typical ECG patterns; lower sensitivity of classic criteriaTreatment patternsRespond well to NSAIDs + colchicineMore frequent corticosteroid use; higher need for immunomodulators (azathioprine, IVIG, IL-1 inhibitors)Recurrence riskLower overall recurrence ratesHigher recurrence rates, especially with autoimmune disease or steroid exposureAutoimmune comorbidityLess commonMuch more common; major driver of recurrencePain perception & reportingMore likely to report classic chest painMore likely to report atypical pain, fatigue, systemic symptomsHealth-seeking behaviorEarlier presentationLater presentationClinician biasPericarditis more readily suspectedSymptoms more often attributed to non-cardiac causesPregnancy considerationsNot applicablePregnancy/postpartum may trigger flares; colchicine now considered safe; IL-1 inhibitors used selectivelyOutcomesGenerally favorable with standard therapyHigher burden of symptoms, more relapses, greater need for advanced therapies Sex-related differences in acute and recurrent pericarditis. Methodology PubMed/MEDLINE, Embase, and Scopus were searched for studies on sex-related differences in acute and recurrent pericarditis, using the keywords “acute pericarditis,” “recurrent pericarditis,” “sex-related differences,” and “gender-related differences.” No date restrictions were applied to include past and current perspectives. Eligible studies focused on adults with acute or recurrent pericarditis and reported findings by sex for epidemiology, etiology, clinical presentation, management, or outcomes. Given the heterogeneity of available evidence and the limited number of studies with sex-specific analyses, this review uses a narrative approach to specifically synthesise and contextualise findings on sex-related differences in acute and recurrent pericarditis. The primary goal is to provide an overview and interpretation of current knowledge in this area, rather than conduct a systematic review or meta-analysis. Sex-related differences in acute and recurrent pericarditis Epidemiology Acute pericarditis consistently affects men more than women, particularly among younger adults, according to recent epidemiologic datasets. For example, in a large, multicentre emergency department chest pain cohort of more than 100,000 visits, men had a higher adjusted risk of acute pericarditis than women [3]. This trend appears in pericarditis-specific studies, where men are more often represented among idiopathic or viral cases [6]. These differences likely reflect true differences in incidence, especially among younger men with viral or idiopathic disease. However, diagnostic patterns may also contribute, as women with chest pain are typically less likely than men to receive non-ischaemic cardiac diagnoses, such as pericarditis, in acute care settings [3]. The epidemiology of recurrent pericarditis is complex. In idiopathic or viral recurrent pericarditis, there is no consistent sex predominance. However, women are more common in certain groups, especially those linked to autoimmune disease and in registries of highly recurrent, treatment-resistant cases. For example, data from the RESONANCE registry, the largest registry for recurrent pericarditis, presented at the 2026 ACC meeting but not yet published, suggested that women make up a slight majority of patients with multiple recurrences [7]. This is likely due to the higher prevalence of autoimmune conditions that increase recurrence risk, rather than a direct effect of sex on recurrence biology. In systemic lupus erythematosus, which affects mostly women, most pericarditis and recurrent pericarditis events also occur in women. However, after accounting for disease activity and treatment, sex does not independently predict recurrence [8]. In summary, the literature indicates that acute pericarditis is diagnosed more often in men, especially younger men with idiopathic or viral forms. For recurrent pericarditis, women are more often affected in autoimmune-mediated, highly recurrent, or refractory cases. Despite these differences, after adjustment for etiology, inflammatory burden, and treatment, sex does not significantly predict prognosis. Contemporary guidelines do not include sex in risk-stratification algorithms for acute or recurrent pericarditis. Etiology The etiology of acute and recurrent pericarditis exhibits a controversial sex-related pattern, reflecting differences in immune regulation, hormones, and comorbidities. In men, pericarditis is most often idiopathic or presumed viral, with enteroviruses and coxsackieviruses commonly implicated [9], [10]. Large series indicate that without systemic disease, most first-episode pericarditis in men is self-limited and triggered by viral or post-infectious causes (10). Women represent 20–30% of reported cases. Similarly, idiopathic or viral causes are most common in women presenting with acute pericarditis. Women, especially those who are middle-aged or postmenopausal, may more frequently have pericarditis with autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, reflecting the higher prevalence of autoimmune disease in females [6], [11], [12]. However, autoimmune etiologies comprise only about 5% of acute pericarditis cases in contemporary cohorts, a proportion similar in women despite their higher prevalence of autoimmune disease [12]. Transitioning to recurrent pericarditis, a clearer etiologic divergence may be observed. Brucato et al. proposed a conceptual framework in which recurrent pericarditis exists along an infectious-autoimmune spectrum. Many cases represent an autoinflammatory or autoimmune process rather than persistent infection [13]. In this context, women are disproportionately represented among patients with autoimmune or immune-mediated recurrent pericarditis. These women often require prolonged anti-inflammatory or immunosuppressive therapy [6], [13], [14]. Men, on the other hand, more frequently experience recurrences following an initial idiopathic or viral episode, and the trigger is presumed to be post-infectious immune activation rather than ongoing systemic autoimmune process [13], [14]. Taken together, these observations underscore that sex is not just a demographic factor but a key modifier of etiologic patterns, especially in recurrent pericarditis, with direct implications for diagnosis and long-term management. Clinical presentation The impact of sex on pericarditis presentation and recurrence is complex. The overall clinical picture likely results from the interplay of multiple factors including biological sex, age, and inflammatory profile (Fig. 1).Fig. 1Factors influencing clinical presentation of pericarditis: The clinical presentation and recurrence of pericarditis result from the interplay of sex, age, and inflammatory phenotype.Fig. 1 Factors influencing clinical presentation of pericarditis: The clinical presentation and recurrence of pericarditis result from the interplay of sex, age, and inflammatory phenotype. Age In younger patients, sex-related differences are pronounced. Men typically display the classic inflammatory pattern: sharp pleuritic pain, pericardial friction rub, and diffuse ST-segment elevation. These hallmarks enable faster recognition and diagnosis [6]. Women more often exhibit atypical or nonspecific symptoms dyspnea, fatigue, or non-pleuritic discomfort and are less likely to show diffuse ST-segment elevation [3]. These distinctions, combined with women's later emergency care and higher rates of autoimmune disease, contribute to delayed diagnosis and underscore broader sex-based disparities in cardiovascular care [6]. Emerging evidence suggests age may influence pericarditis more than sex. Men present younger; women, later. This age gap affects how sex differences appear. Bizzi et al. showed that sex differences are more pronounced in younger patients, but diminish with age, as older adults of both sexes show a similar clinical pattern. In these older groups, male predominance lessens, and women account for a greater proportion of recurrent cases [15]. This perhaps reflects age-related immune changes that may outweigh sex-based immune differences and lead to a more uniform disease pattern. Inflammatory markers Inflammatory markers such as C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) are often elevated in acute pericarditis. Evidence for sex-related differences in these biomarkers is inconclusive. The largest cohort to date (729 patients) found similar CRP and ESR levels in men and women, even though women had a higher prevalence of autoimmune disease [3]. Additionally, studies evaluating sex differences in pericarditis risk reported no significant differences in biomarker elevation between sexes. These markers reflect disease activity rather than patient sex [6], [15]. On the other hand, it appears that the inflammatory phenotype is likely a more meaningful determinant of sex-related variation. In younger patients with CRP-positive pericarditis, men and women show similar presentations: pleuritic chest pain and classic inflammatory features. Sex differences emerge in low-grade or CRP-negative pericarditis, where symptoms are less specific, and diagnosis is more varied. Women are overrepresented in the CRP-negative group. However, studies including Mascolo et al. find no sex difference in biomarker elevation [CRP, ESR, interleukin 6 (IL-6), serum amyloid A (SAA), soluble urokinase plasminogen activator receptor (suPAR)] [16]. 25% of patients had normal CRP and were more often female (67.9% vs 42.0%). Still, CRP and ESR values did not differ between sexes when inflammation was present. Profiling in CRP-negative patients showed normal IL-6 and suPAR, and only limited SAA elevation, without sex differences. These findings suggest that the non-inflammatory phenotype is not due to sex-specific cytokine or acute-phase responses but rather reflects distinct disease biology independent of sex (Fig. 2).Fig. 2Influence of age & inflammatory markers on clinical presentation: CRP and ESR elevations show no major sex differences when inflammation is present. Differences emerge mainly in phenotype distribution (e.g., women more often CRP-negative), not in biomarker magnitude. In older adults, sex-related differences become less distinct because inflammatory responses are blunted. Presentation is possibly driven more by age-related immune remodeling than by sex.Fig. 2 Influence of age & inflammatory markers on clinical presentation: CRP and ESR elevations show no major sex differences when inflammation is present. Differences emerge mainly in phenotype distribution (e.g., women more often CRP-negative), not in biomarker magnitude. In older adults, sex-related differences become less distinct because inflammatory responses are blunted. Presentation is possibly driven more by age-related immune remodeling than by sex. Overall, the data suggest that sex affects the likelihood of having a specific inflammatory phenotype, such as CRP-negative disease, rather than the intensity of inflammation. Age alters these patterns and lessens sex differences in older people. Therefore, pericarditis clinical presentation and recurrence result from the interplay of sex, age, and inflammatory phenotype and cannot be explained by any single factor alone. Complications and outcomes Recurrence After an initial episode of acute pericarditis, the recurrence rate is about 20–30% [17]. Women are more likely than men to experience multiple relapses, particularly with autoimmune comorbidities or corticosteroid exposure [6], [13]. This increased risk in women is also reflected in the prevalence of autoimmune-mediated pericarditis, which often leads to chronic disease and usually requires immunomodulatory therapy [13], [14]. In contrast, men with idiopathic or viral pericarditis generally have a more favorable course, with lower risk of chronicity and fewer treatment escalations [9]. Further illustrating the complexity, a JAMA Network Open cohort study of 590 SLE patients with pericarditis (90.5% women) found that sex was not linked to recurrence risk. Over a median follow-up of 6.7 years, 20.3% had recurrence. Multivariable analysis identified younger age, prednisone exposure, active SLE, and a shorter interval since the initial episode as independent predictors of recurrence. Most recurrences were in women, reflecting SLE's female predominance [8]. Pericardial effusion Pericardial effusion is a recognised complication of pericarditis. Earlier studies, based on small, single-centre cohorts with limited sex diversity, suggested that men were more likely to experience severe effusion in acute pericarditis. This was attributed to a higher rate of viral pericarditis in men, which is linked to more prominent effusions, rather than a true sex-based difference. Notably, this difference disappeared after adjustment for inflammatory markers and etiology [18]. More recently, evidence from the largest sex-stratified cohort shows no significant sex differences in echocardiographic features, specifically in effusion presence or size [6]. Hospitalisation Earlier descriptive studies reported higher hospitalisation rates for acute pericarditis in men. However, sampling bias accounted for these findings, since study populations did not include all pericarditis patients. Early cohorts focused on younger men with viral pericarditis at a time when most such cases were hospitalised. Newer studies now show that hospitalisation for acute pericarditis is not sex-dependent in current practice [6]. Both the 2015 and forthcoming 2025 European Society of Cardiology (ESC) pericardial disease guidelines do not identify sex as a determinant of hospitalisation risk. Accordingly, these findings indicate that sex does not influence the risk of hospitalisation in pericardial disease [12], [19]. Myopericarditis Although myopericarditis has long been seen more often in men, this pattern reflects overall trends in myocardial inflammation, not detailed sex-specific data in acute pericarditis. Large reviews show men are two to four times more likely than women to have myocarditis [11]. In a prospective cohort study by Imazio et al., including about 500 patients, myocardial involvement occurred predominantly in younger males, consistent with the recognised male predominance of viral myopericarditis. Men were the majority of cases with elevated cardiac biomarkers and imaging evidence of myocardial inflammation, while women were less frequently affected and tended to present with isolated pericardial disease. Despite these sex-related differences in frequency of myocardial involvement, the clinical course and prognosis were uniformly favorable for both sexes. Both men and women with myopericarditis had preserved left ventricular systolic function, low complication rates, and excellent long-term outcomes comparable to those with isolated pericarditis. Sex did not alter the prognostic impact of myocardial involvement, and no differences were found in recovery, recurrence, or adverse events [20]. In another cohort of patients with acute myocarditis, clear sex-related differences emerged in both the clinical phenotype and diagnostic profile of myocardial involvement. Men made up most myocarditis cases and more often showed classical features of acute myocardial injury. These included higher peak troponin concentrations, more extensive late gadolinium enhancement on cardiac magnetic resonance imaging, and chest pain as the main symptom. In contrast, women less often had overt myocardial necrosis and showed a more mixed clinical profile, with dyspnea and nonspecific systemic symptoms more common than in men. Despite these differences in how myocardial injury appeared, left ventricular systolic function, arrhythmic complications, and short-term outcomes were similar for both men and women. Overall, these findings suggest that while men are more likely to have myocardial inflammation with stronger biomarker and imaging evidence, myopericarditis has a similarly benign prognosis in both sexes when current diagnostic and therapeutic strategies are used [21]. Other complications The risk of severe complications, such as constrictive pericarditis, remains low in idiopathic and viral pericarditis. In contrast, autoimmune or systemic inflammatory present a higher long-term complication risk in women [10]. These sex-based differences indicate the need for tailored diagnostic and individualized management strategies to optimize outcomes for all patients with pericarditis. Management and response to treatment The 2025 ESC Guidelines recommend NSAIDs, colchicine, and targeted anti-inflammatory therapy for all patients. Despite these universal recommendations, real-world data reveal sex-specific therapeutic patterns and responses [19]. Building on these recommendations, men generally respond favourably to standard first-line therapy with NSAIDs and colchicine, exhibiting lower rates of treatment escalation [9], [22]. Although colchicine reduces the risk of recurrence by approximately 50% in both sexes, men tend to experience fewer refractory or steroid-dependent disease courses, likely reflecting the predominance of non-autoimmune etiologies [22]. Women, especially those with autoimmune comorbidities, require corticosteroids or immunomodulatory therapy more often. Autoimmune pericarditis disproportionately affects women, carries a higher inflammatory burden, and leads to a relapsing course [6], [11]. As a result, women are more frequently exposed to corticosteroids, despite guidelines recommending minimizing steroid use because of its established link to increased recurrence risk [17], [23]. This management likely drives the higher rate of recurrent and chronic pericarditis in women. As these sex-based management challenges persist, advanced therapies (IL-1) inhibitors such as anakinra and rilonacept, have significantly improved recurrent pericarditis management. Although clinical trials show substantial reductions in recurrence rates and rapid symptom resolution, data stratified by sex remain limited [14], [24]. In contrast, observational data indicate that women, likely due to a higher prevalence of autoimmune or autoinflammatory disease, more often require IL-1 blockade and may derive particular benefit from these agents [6], [14]. In summary, although guideline-directed therapy is similar for both sexes, women more often require escalation of treatment, are exposed to higher corticosteroid levels, and rely more on immunomodulatory or biologic therapies than men. Recognising these specific contrasts highlights the need for earlier identification of autoimmune phenotypes in women, stricter steroid management, and swifter initiation of targeted therapies to optimize pericarditis outcomes. Biological, hormonal, environmental, and social bases of sex-related differences in pericarditis Sex-related differences in cardiovascular diseases result from complex interactions involving chromosomes, hormones, immune regulation, and gender-linked environmental and social factors [25]. Key mechanisms include the effects of sex hormones on immunity: estrogens enhance humoral and cell-mediated immune responses, promote B-cell survival, and modulate T-cell differentiation, contributing to the higher prevalence of autoimmune diseases in women [26], [27], [28]. In contrast, androgens generally suppress immune activation and may protect against chronic inflammatory responses [29]. These hormonal effects can intensify pericardial inflammation or promote chronicity and recurrence in women, especially when systemic autoimmune disease is present. Additionally, X-chromosome–linked immune regulatory genes and sex-specific epigenetic patterns further shape immune responses, increasing the risk of autoimmune-mediated pericarditis and recurrent episodes in women [30], [31]. While direct mechanistic studies of pericarditis are limited, these immunological mechanisms clarify how environmental and social determinants can also influence sex differences in pericarditis. Sex-related factors such as differences in symptom reporting, healthcare seeking behaviors, and clinician risk assessment negatively affect outcomes in women with other cardiovascular diseases and likely apply to pericarditis as well [32], [33], [34]. Moreover, sex-specific differences in pain perception and communication among women may cause diagnostic uncertainty or misattribution of symptoms [35], [36]. Thus, biological predispositions, combined with social and environmental factors, shape the clinical presentation in both sexes. Current evidence supports a multifactorial model for sex-related differences in acute and recurrent pericarditis. Hormones, sex-linked immune regulation, autoimmune comorbidities, and gender-related diagnostic and therapeutic pathways all play significant roles. Most current understanding comes from broader cardiovascular and autoimmune research, highlighting the need for further mechanistic and sex-stratified studies. Integrating these approaches is key to developing effective, sex-sensitive diagnostic and management strategies. Pericarditis in pregnancy: key clinical considerations Pericarditis during pregnancy presents unique diagnostic and therapeutic challenges. Clinicians must carefully evaluate maternal and fetal safety, disease activity, and medication compatibility. Pericarditis is uncommon in pregnancy. However, women of reproductive age—especially those with underlying autoinflammatory or autoimmune disorders—may develop acute or recurrent episodes. These cases require individualized management strategies [37]. The 2025 ESC Guidelines for the Management of Pericardial Diseases emphasize that controlling pericardial inflammation leads to better maternal and neonatal outcomes. Evidence-based therapy throughout pregnancy is crucial [19]. Pharmacological management Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line therapy during the first and second trimesters. They should be discontinued after 20 to 24 weeks of gestation because of the risk of premature ductus arteriosus closure and oligohydramnios [19]. Low-dose aspirin is considered safe throughout pregnancy and may be continued when clinically indicated. Colchicine therapy Historically, colchicine use during pregnancy was approached with caution due to its anti-mitotic properties. However, extensive data from women with familial Mediterranean fever (FMF) and Behçet disease show that colchicine exposure in pregnancy is not linked to higher rates of miscarriage, congenital malformations, or neonatal complications [38], [39], [40]. Studies specifically evaluating colchicine in pregnant women with recurrent pericarditis also report favorable maternal and fetal outcomes [41]. As a result, major international guidelines now consider colchicine compatible with all stages of pregnancy and breastfeeding [19], [42], [43]. No adverse effects have been reported in breastfed infants in case-control studies and case series [38], [40]. Corticosteroid therapy Corticosteroids may be used when necessary, especially in autoimmune-mediated pericarditis. However, their use should be minimized because they increase recurrence risk and may cause maternal metabolic complications [19], [37]. When indicated, low to moderate doses of prednisone or prednisolone are preferred due to their limited placental transfer. Interleukin-1 inhibitor therapy Recent evidence supports using (IL-1) inhibitors, especially anakinra, as a steroid-sparing option for selected pregnant patients with refractory or recurrent pericarditis. Anakinra is a recombinant analogue of the endogenous IL-1 receptor antagonist. This naturally occurs in maternal circulation and is detectable in breast milk. A recent multinational case series reported favorable maternal and neonatal outcomes in 17 pregnancies among 14 women who received anakinra throughout pregnancy and breastfeeding. There were no congenital anomalies, neonatal infections, or drug-related adverse events. Disease flares were managed with dose adjustments. This allowed continued inflammatory control while minimizing corticosteroid exposure [44]. Although data remain limited, these findings suggest that IL-1 blockade may be viable in selected cases. Maternal and fetal outcomes Across studies, control of disease activity—not the specific medication used—is most important for pregnancy outcomes. Active pericarditis, especially when recurrent or autoimmune-mediated, raises risks of preterm delivery and maternal morbidity. Well-controlled disease is generally compatible with normal pregnancy outcomes [19], [41]. Multidisciplinary management with cardiology, rheumatology, and maternal-fetal medicine is recommended to optimize care. Table 2 summarizes the key pregnancy related considerations.Table 2Summary of key considerations in pericarditis during pregnancy.Key pointsEpidemiologyPericarditis is uncommon in pregnancy; cases occur mainly in women of with underlying autoimmune disease.TreatmentIndividualized management is required.NSAID: First-line therapy in the 1st and 2nd trimesters; discontinue after 20–24 weeks. Low-dose aspirin is safe throughout pregnancy when indicated.Colchicine: Historically avoided, but evidence shows safety and it is considered compatible with all stages of pregnancy and breastfeeding by major international guidelines.Corticosteroid: Reserved for selected cases, especially autoimmune-mediated disease due to recurrence risk and maternal metabolic effects. Prednisone/prednisolone preferred because of limited placental transfer.IL-1 inhibitor like Anakinra has reassuring safety data but reserved for refractory or recurrent disease.Multidisciplinary care is recommended.OutcomesDisease control is the strongest predictor of outcomes. Active or recurrent pericarditis increases risks of preterm delivery and maternal morbidity. Table 2Summary of key considerations in pericarditis during pregnancy.Key pointsEpidemiologyPericarditis is uncommon in pregnancy; cases occur mainly in women of with underlying autoimmune disease.TreatmentIndividualized management is required.NSAID: First-line therapy in the 1st and 2nd trimesters; discontinue after 20–24 weeks. Low-dose aspirin is safe throughout pregnancy when indicated.Colchicine: Historically avoided, but evidence shows safety and it is considered compatible with all stages of pregnancy and breastfeeding by major international guidelines.Corticosteroid: Reserved for selected cases, especially autoimmune-mediated disease due to recurrence risk and maternal metabolic effects. Prednisone/prednisolone preferred because of limited placental transfer.IL-1 inhibitor like Anakinra has reassuring safety data but reserved for refractory or recurrent disease.Multidisciplinary care is recommended.OutcomesDisease control is the strongest predictor of outcomes. Active or recurrent pericarditis increases risks of preterm delivery and maternal morbidity. Summary of key considerations in pericarditis during pregnancy. Conclusion Sex-related differences in acute and recurrent pericarditis significantly influence disease etiology, clinical presentation, therapeutic response, and patient outcomes. Men typically present with classic symptoms, which facilitate timely recognition and intervention. In contrast, women, especially those with autoimmune comorbidities, more frequently exhibit atypical symptoms, experience diagnostic delays, and have higher relapse rates. These disparities are driven by sex-specific immune and hormonal mechanisms, gender-associated behaviors, and diagnostic bias. Larger, sex-stratified studies are required to clarify these underlying mechanisms. Despite these observed disparities, the 2025 ESC Guidelines for myocarditis and pericarditis fail to provide specific recommendations for sex-based differences in managing acute or recurrent pericarditis. The interactions between sex hormones and immune responses in pericardial disease remain inadequately understood. To address these gaps, it is essential for future research to prioritize prospective, sex-stratified studies with standardized outcome measures, ensuring inclusion of women across all reproductive stages. Clinicians and researchers should also advocate for guideline updates that incorporate sex-specific recommendations and expand understanding of hormonal and immune interactions in pericardial disease. Future directions Future research on sex-related differences in pericarditis should prioritize mechanistic and clinical investigations aimed at actionable outcomes. Specifically, studies should target understanding why women experience higher recurrence rates and greater need for immunomodulatory therapy. Key areas include sex-specific immune pathways, hormonal influences, and genetic or epigenetic factors that drive disease expression and treatment responses. To advance pericarditis research, prioritize sex-stratified analyses in clinical trials and cohort studies to generate necessary data for tailored treatments. Refine diagnostic protocols by addressing the atypical symptoms and diagnostic delays frequently experienced by women. Direct research towards developing sex-specific diagnostic tools to improve detection and risk assessment. Research on pericarditis in pregnancy remains a critical gap. To address this, establish robust prospective registries, conduct comprehensive follow-up studies, and prioritize integration of mechanistic, sex-stratified, and pregnancy-focused studies. These specific actions are essential to guide management across the reproductive lifespan and to advance precision medicine for acute and recurrent pericarditis. CRediT authorship contribution statement Nouf Alanazi: Writing – review & editing, Writing – original draft, Data curation, Conceptualization. Ethical statement This article is a literature review and does not contain any original studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required for this work. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors received no financial support for the research. As this is a review of existing literature and does not involve individual participants, informed consent was not applicable. Declaration of competing interest I have no relationships relevant to the contents of this paper to disclose.